alzheimers news-keep an eye on these two new alzheimers treatments

ALZHEIMERS NEWS-KEEP AN EYE ON THESE TWO ALZHEIMERS TREATMENTS

if you are living in the alzheimers world or you see it in your future
you should pay attention to these two new drugs

eli lillys donanemab
biogens aducanumab 

they are the closest drugs to being approved for use that will be used to slow down or prevent alzheimers disease
the earlier in the disease they are given the better they will probably work

they both are antibodies against parts of the beta amyloid that form plaques that get deposited in the brain
they remove this beta amyloid plaques
a year or more after they are given the amyvid pet scans show with both of these drugs that the plaques are mostly gone

they both shown a decrease in the effect of tau in the brain after that year also

they both show a slowing of cognitive decline
donanemab by 30%
aducanumab by 20+%

in the alzheimers world 20-30% slowing of cognitive decline is significant

with aducanumab there also is an improvement in less neuroinflammation

with alzheimers amyloid shows up first as plaques then tau tangles appear then neuroinflammation moves in 
all three kill brain cells

donanemab is in phase 2 studies and will be entering phase 3 soon and is probably going to ask for early evaluation of the drug by the fda

aducanumab has finished phase 3 studies and we will know by june or july if the fda will approve its use

i of course am partial to aducanumab since i was in the study for almost 3 years
i got 18 months of placebo 
then
received 7 months of the dose of aducanumab that has shown good results

i go to ucla next month to start my revaluation to restart the infusions
if approved i will receive at least 18 months of infusions

the fda will either approve aducanumab in june
or
require a longer phase 4 study of its use
or
worse will deny its use

if they require a phase 4 study i hope to enter that one if i can

these two drugs are the only ones that can potentially help me
its unlikely any of the other ones that are in the research clinical studies will arrive in time to be of help to me

i am on aricept (donepezil) thats usually used when you first are diagnosed with alzheimers disease
it the aricept doesnt come close to either of these in how well it works to slow down cognitive decline

what they may find with these two drugs aducanumab and donanemab is that they work the best when given to people who are 
prealzheimers 

prealzheimers is where you have normal memory but have positive biomarkers ie amyloid pet scans and or tau pet scans or spinal fluid for amyloid or tau or coming soon positive blood tests

but
for me 
these are the two choices
and
i have already chosen one of these
aducanumab

two of the biggest drawbacks to these two drugs will be 

the cost of probably $5000+ a month
since i am in the clinical study i dont have to pay for it

the availability of infusions centers to give them each month
its predicted that the system will be overwhelmed with people wanting these infusions

at least i will get aducanumab for 18 months

the organicgreen doctor